PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza

Publication Date: 31 October 2018

This guidance has been approved for use in Scotland by the Scottish Health Protection Network Guidance Group (SHPN-GG). The guidance should be used in conjunction with the SHPN addendum.

The PHE guidance on use of antiviral agents for the treatment and prophylaxis of influenza covers:

  • definitions
  • treatment of suspected or confirmed influenz
  • post-exposure prophylaxis supply of zanamivir acqueous solution
  • use of anti-virals in pregnancy, breastfeeding, hepatic or renal dysfunction

Key changes since the last version

The major changes from version 8.0 (2017 to 2018) include:

  • Further information on the recommended dosing for renal dysfunction in adults and children for treatment (Section 1.3.2) and prophylaxis (Section 2.1.2)
  • Updated information on Peramivir and Baloxavir Marboxil (Section 1.3.5)
  • Additional information on antivirals and breastfeeding (Appendix 1)
  • Updates to the FAQ on management of neonates exposed to mothers with confirmed seasonal influenza (FAQs – page 39)

Resource information

Publisher:
Public Health England
Publication type:
Guideline and Guidance